Prevalence of neutralising antibodies against SARS-CoV-2 in acute infection and convalescence: A systematic review and meta-analysis

Savage, Helen, Santos, Victor S, Edwards, Thomas, Giorgi, Emanuele, Krishna, Sanjeev, Planche, Timothy D, Staines, Henry M, Fitchett, Joseph R A, Kirwan, Daniela E, CubasAtienzar, Ana, Clark, David J, Adams, Emily ORCID: https://orcid.org/0000-0002-0816-2835 and Cuevas, Luis ORCID: https://orcid.org/0000-0002-6581-0587 (2021) 'Prevalence of neutralising antibodies against SARS-CoV-2 in acute infection and convalescence: A systematic review and meta-analysis'. PLoS neglected tropical diseases, Vol 15, Issue 7, e0009551.

	Text NAB_PNTD - Luic Cuevas.docx - Accepted Version Restricted to Repository staff only Download (217kB)
Preview	Text journal.pntd.0009551.pdf - Published Version Available under License Creative Commons Attribution. Download (1MB) | Preview

Abstract

BACKGROUND
Individuals infected with SARS-CoV-2 develop neutralising antibodies. We investigated the proportion of individuals with SARS-CoV-2 neutralising antibodies after infection and how this proportion varies with selected covariates.

METHODOLOGY/PRINCIPAL FINDINGS
This systematic review and meta-analysis examined the proportion of individuals with SARS-CoV-2 neutralising antibodies after infection and how these proportions vary with selected covariates. Three models using the maximum likelihood method assessed these proportions by study group, covariates and individually extracted data (protocol CRD42020208913). A total of 983 reports were identified and 27 were included. The pooled (95%CI) proportion of individuals with neutralising antibodies was 85.3% (83.5-86.9) using the titre cut off >1:20 and 83.9% (82.2-85.6), 70.2% (68.1-72.5) and 54.2% (52.0-56.5) with titres >1:40, >1:80 and >1:160, respectively. These proportions were higher among patients with severe COVID-19 (e.g., titres >1:80, 84.8% [80.0-89.2], >1:160, 74.4% [67.5-79.7]) than those with mild presentation (56.7% [49.9-62.9] and 44.1% [37.3-50.6], respectively) and lowest among asymptomatic infections (28.6% [17.9-39.2] and 10.0% [3.7-20.1], respectively). IgG and neutralising antibody levels correlated poorly.

CONCLUSIONS/SIGNIFICANCE
85% of individuals with proven SARS-CoV-2 infection had detectable neutralising antibodies. This proportion varied with disease severity, study setting, time since infection and the method used to measure antibodies.

Item Type:	Article
Subjects:	QW Microbiology and Immunology > Viruses > QW 160 Viruses (General). Virology QW Microbiology and Immunology > Antigens and Antibodies. Toxins and Antitoxins > QW 575 Antibodies W General Medicine. Health Professions > W 20.5 Biomedical research WC Communicable Diseases > Virus Diseases > Viral Respiratory Tract Infections. Respirovirus Infections > WC 505 Viral respiratory tract infections
Faculty: Department:	Clinical Sciences & International Health > Clinical Sciences Department
Digital Object Identifer (DOI):	https://doi.org/10.1371/journal.pntd.0009551
Depositing User:	Julie Franco
Date Deposited:	27 Jul 2021 10:55
Last Modified:	27 Jul 2021 10:55
URI:	https://archive.lstmed.ac.uk/id/eprint/18447

Statistics

View details

Actions (login required)

Edit Item